DOCSLIB.ORG

Supplementary Materials and Methods

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Truncating mutations in YIF1B cause a progressive encephalopathy with various degrees of mixed movement disorder, microcephaly, and epilepsy. Item Type Article Authors AlMuhaizea, Mohammed; AlMass, Rawan; AlHargan, Aljouhra; AlBader, Anoud; Medico Salsench, Eva; Howaidi, Jude; Ihinger, Jacie; Karachunski, Peter; Begtrup, Amber; Segura Castell, Monica; Bauer, Peter; Bertoli-Avella, Aida; Kaya, Ibrahim H; AlSufayan, Jumanah; AlQuait, Laila; Chedrawi, Aziza; Arold, Stefan T.; Colak, Dilek; Barakat, Tahsin Stefan; Kaya, Namik Citation AlMuhaizea, M., AlMass, R., AlHargan, A., AlBader, A., Medico Salsench, E., Howaidi, J., … Kaya, N. (2020). Truncating mutations in YIF1B cause a progressive encephalopathy with various degrees of mixed movement disorder, microcephaly, and epilepsy. Acta Neuropathologica. doi:10.1007/ s00401-020-02128-8 Eprint version Post-print DOI 10.1007/s00401-020-02128-8 Publisher Springer Nature Journal Acta neuropathologica Rights Archived with thanks to Acta neuropathologica Download date 06/10/2021 17:47:21 Link to Item http://hdl.handle.net/10754/661480 SUPPLEMENTARY MATERIALS AND METHODS Human Subjects The study was approved by institutional review boards (RAC# 2120022) at King Faisal Specialist Hospital and Research Centre and written informed consents were taken from the participants. Nucleic Acid Extraction, PCR, and Sanger Sequencing Peripheral blood samples were used for DNA extraction using Gentra’s Puregene Blood Kit, and QIAamp Venlo, Netherlands. Nucleic acid quality and quantity were determined using NanoDrop ND-1000 (ThermoFisher Scientific, Inc., Waltham, MA, US) and 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, US) equipment. Primers were designed using Primer 3 and tested on human control DNA. PCRs were performed according to standard protocols and successfully amplified PCR products were directly used for Sanger sequencing using one of the PCR primers tagged with M13 universal site. Autozygosity Mapping DNA was also used for genome-wide SNP interrogation using GeneChip axiom arrays. SNP calls were extracted using Affymetrix’s Genotyping Console and transferred to AutoSNPa software for autozygome analysis. Runs of homozygosity (ROH) across the autozygome of the affected individuals were determined as previously described [1, 2, 8]. Whole Exome Sequencing (WES), Variant Calls and Filtering Case 1-4: TruSeq Exome Enrichment kit (Illumina, San Diego, CA, USA) was used to capture exomic sequences for library preparation and enrichment. The established libraries were run and sequenced on Illumina HiSeq 2000 Sequencer. WES data analysis and filtering were performed as previously published [1, 2, 4, 8]. Case 5: Whole exome sequencing was performed at CENTOGENE AG, as previously described [12]. Case 6: Using genomic DNA from the proband and parents, the exonic regions and flanking splice junctions of the genome were captured using the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). Massively parallel (NextGen) sequencing was done on an Illumina system with 100bp or greater paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19, and analyzed for sequence variants using a custom-developed analysis tool. Additional sequencing technology and variant interpretation protocol has been previously described [9]. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page. (http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/)" Age of Mutation Calculation The border of ROH among the affected individuals (Supplementary Figure 1A) was determined using AutoSNPa software (Chr19:35,473,940-39,941,310) using the UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly. Sex-average recombination rates (RR) were taken from DECODE. The sum of the RR in the region is 5.35 centiMorgan. Age of the mutation is therefore approximately 37 generations, corresponding to 925 years (assuming one generation is 25 years) [1]. Pathway and Gene Network Analysis of YIF1B-Co-expressed genes It has been reported that co-expressed genes are likely to be functionally related and may provide important information on gene function and its possible regulation [10, 15]. We used publicly available datasets with over 46,000 human RNAseq to identity genes that are co-expressed with YIF1B [2]. We selected the most strongly associated genes with YIF1B with Pearson correlation (r) > 0.9 (171 genes). We then performed gene ontology enrichment and interaction network analyses using Ingenuity Pathways Analysis (IPA) 6.4 (Ingenuity Systems, Mountain View, CA). Computational structural analysis RaptorX [7] was used to predict protein structural disorder and secondary structure. iTasser [16] was used to build an initial model for the structured region of the protein (residues 69-314), whereas RaptorX was used to build a model for the flexible N-terminal 65 residues. SWISS-MODEL [3] was used combined both models. Models were manually inspected, and mutations evaluated, using the PyMOL program (pymol.org). SUPLEMENTARY FIGURE LEGENDS Supplementary Figure 1. A. Extended large ROH (black region) shared among the index cases (F1, F2, and F3) is framed with red lines. Blue line points location of YIF1B on chromosome 19 and red arrows show beginning and end of the run. Right panel presents selected non-affected individuals from the same families. Based on the shared ROH regions, the age of this founder mutation can be estimated to be 925 years. B. Multiple sequence alignment of all three YIF1B variants indicating high conservation of the amino acids in the regions among various species. Supplementary Figure 2. Protein and mRNA expressions of YIF1B, from the Protein Atlas (http://www.proteinatlas.org) and FANTOM5 [5, 6, 11, 13, 14]. According to FANTOM5 mRNA expression levels of the gene are the highest in different brain regions in comparison to other organs except for lymph node and liver. Supplementary Figure 3. Immunocytochemistry in three different cells lines (HPA039328: U-251 MG; HPA039328: U-2 OS; HPA039328: A549) revealed location of YIF1B mainly in vesicles and localized to the Golgi apparatus. Green labeled molecules are YIF1B. Data is taken from The Human Protein Atlas [11, 13, 14]. Supplementary Figure 4. Immunohistochemistry on normal brain tissue using two different primary antibodies targeting YIF1B. A. IHH results from cerebral cortex of a male brain. B. IHH results were obtained using a different antibody in the same region of another male at different age. Data is taken from The Human Protein Atlas.[11, 13, 14] Supplementary Figure 5. Gene interaction network analysis of YIF1B co-expressed genes. Genes in the network are co-expressed with YIF1B in over 46,000 human RNASeq data (with Pearson correlation > 0.9). Nodes represent genes with their shape representing the functional class of the gene product, and edges indicate biological relationship between the nodes. YIF1B co-expressed genes are significantly associated with neurological disease and developmental disorders (p <0.01) (indicated in purple). Supplementary Figure 6. A) Secondary structure prediction for wild type (left) and mutant YIF1B (right). B) Protein structural disorder prediction for wild type (left) and mutant YIF1B (right). C) Sequences from YIF1B wild-type and both mutants are compared. Color-coding corresponds to Figure 1, with the amino acid sequence resulting from the frame-shifts shown in bold (these residues are not shown in Figure 1). SUPPLEMENTARY FIGURE 6 A B C SUPLEMENTARY TABLES Supplementary Table 1. Clinical descriptions of the patients from the families. FAMILY II:2; Family 1 II:3; Family 1 II:2; Family 2 II:2; Family 3 II:3; family 4 II:6; Family 5 GENDER F F F F M F AGE AT PRESENTATION 6-MONTH BIRTH 8-MONTH 6-MONTH NA 6-MONTH AGE AT FIRST EVALUATION 7 YEARS 17-MONTH 4 YEARS 2 YEARS NA 23 MONTH AGE AT LAST EVALUATION 9 YEARS 4 YEARS 11 YEARS 11 YEARS NA 7 YEARS OUTCOME (ALIVE OR DEAD) ALIVE ALIVE ALIVE ALIVE NA ALIVE ETHNICITY ARAB ARAB ARAB ARAB NA SOMALI PRENATAL AND BIRTH NA PRENATAL COMPLIACTIONS (E.G. IUGR) NO NO NO possible IUGR NA NO GESTATIONAL AGE TERM TERM TERM FULL TERM NA FULL TERM BIRTH WEIGHT (SGA) NORMAL NORMAL NORMAL 2.16 KG NA UNKNOWN BIRTH LENGTH NORMAL NORMAL NORMAL 50 CM NA UNKNOWN BIRTH HEAD CIRCUMFERENCE NORMAL NORMAL NORMAL 32 CM NA UNKNOWN (MICROCEPHALY) GROWTH NA FTT (CURRENT WEIGHT) YES YES YES 10% PERCENTILE NA NO SHORT STATURE (CURRENT HEIGHT) YES YES YES 10% NA NO MICROCEPHALY YES YES YES YES NA NO DEVELOPMENT AND BEHAVIOR NA GLOBAL DEVELOPMENTAL DELAY YES YES YES - PROFOUND YES NA YES HYPOTONIA AXIAL HYPOTONIA AXIAL HYPOTONIA AXIAL HYPOTONIA AXIAL HYPOTONIA NA YES BEST GROSS MOTOR MILESTONE 1/2 ROLL ROLL OVER NOT ROLLING NOT ROLLING NA NOT ROLLING BEST FINE MOTOR MILESTONE REACH AND HOLD HOLD -IMMATURE HOLD -IMMATURE HOLD OBJECT NA REACH FOR OBJECTS OBJECT BEST LANGUAGE MILESTONE CHOOING LIKE SOUNDS BABBLES SOUNDS SOUNDS NA VOCALISATION SOCIAL DEVELOPMENT SOCIAL SMILE SOCIAL SMILE SMILE SOCIAL SMILE NA SOCIAL SMILE IRRITABILITY YES, INTERMITTENT YES, MORE WITH STRESS YES MORE ON OCCASIONAL NA YES AND TRAVEL LEVETIRACETAM VISUAL ABNORMALITY NO NO NO NO NA CORTICAL BLINDNESS, HYPERMETROPIA, ASTIGMATISM HEARING IMPAIRMENT NO NO NO NO NA NO AURISTIC FEATURES NO NO NO NO NA ? N/A MOVEMENT DISORDER NA DYSTONIA UPPER AND LOWER LIMB DYSTONIA LIMB DYSTONIA LIMB UPPER MORE NA NO DYSTONIA LIMBS THAN LOWER SPASTICITY LIMB LIMB SEVERE LIMB SPASTICITY MILD LIMB SPASTICITY NA SPASTIC QAUDRIPLEGIA DYSKINESIA LIMB AND FACE CHOREA WITH DYSTONIA LIMB FACE AND DISTAL NA ND LIMBS RESPONSE TO LEVODOPA/CARBIDOPA NO NO N/D NO RESPONSE NA ND RESPONSE TO BACLOFEN PARTIAL NOT USED NOT USED NA ND RESPONSE TO TRIHEXPHENYDIL PARTIAL PARTIAL IMPROVEMENT ND PARTIAL NA ND IMPROVEMENT SEIZURES NO NO YES NO NA YES EEG ABNORMAL 1: EXCESSIVE NORMAL/AWAKE ABNORMAL III (AWAKE ND NA DIFFUSE HIGH FAST ACTIVITY AND SLEEP). AMPLITUDE SLOWING BACKGROUND SLOW WITH SUPERIMPOSED ACTIVITY. SLOW SPIKE FREQUENT AND WAVE COMPLEX, GENERALIZED AND GENERALIZED. SPIKES, MULTIFOCAL MULTIREGIONAL. PAROXYSMAL INTERMITTENT SLOW EPILEPTIFORM ACTIVITY, GENERALIZED.
Recommended publications
  • Nuclear and Mitochondrial Genome Defects in Autisms

    Nuclear and Mitochondrial Genome Defects in Autisms

    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • A Genomic Screen for Activators of the Antioxidant Response Element

    A Genomic Screen for Activators of the Antioxidant Response Element

    A genomic screen for activators of the antioxidant response element Yanxia Liu†, Jonathan T. Kern‡, John R. Walker§, Jeffrey A. Johnson‡, Peter G. Schultz§¶ʈ, and Hendrik Luesch†ʈ †Department of Medicinal Chemistry, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 32610; ‡Department of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin, 777 Highland Avenue, Madison, WI 53705; §Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121; and ¶Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 Contributed by Peter G. Schultz, January 31, 2007 (sent for review December 13, 2006) The antioxidant response element (ARE) is a cis-acting regulatory activation, translocates into the nucleus and transcriptionally acti- enhancer element found in the 5؅ flanking region of many phase II vates ARE-dependent genes after recruiting Maf proteins (2). The detoxification enzymes. Up-regulation of ARE-dependent target upstream regulatory mechanisms by which ARE-activating signals genes is known to have neuroprotective effects; yet, the mechanism are linked to Nrf2 remain to be fully elucidated. It has been of activation is largely unknown. By screening an arrayed collection demonstrated that reactive sulfhydryl groups of Keap1 are sensors of Ϸ15,000 full-length expression cDNAs in the human neuroblas- for induction of phase II genes (13), leading to the proposal that the toma cell line IMR-32 with an ARE-luciferase reporter, we have Nrf2/Keap1 interaction represents a cytoplasmic sensor for oxida- identified several cDNAs not previously associated with ARE activa- tive stress. However, 1-phosphatidylinositol 3-kinase (PI3K), tion.
  • Systems Analysis Implicates WAVE2&Nbsp

    Systems Analysis Implicates WAVE2&Nbsp

    JACC: BASIC TO TRANSLATIONAL SCIENCE VOL.5,NO.4,2020 ª 2020 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/). PRECLINICAL RESEARCH Systems Analysis Implicates WAVE2 Complex in the Pathogenesis of Developmental Left-Sided Obstructive Heart Defects a b b b Jonathan J. Edwards, MD, Andrew D. Rouillard, PHD, Nicolas F. Fernandez, PHD, Zichen Wang, PHD, b c d d Alexander Lachmann, PHD, Sunita S. Shankaran, PHD, Brent W. Bisgrove, PHD, Bradley Demarest, MS, e f g h Nahid Turan, PHD, Deepak Srivastava, MD, Daniel Bernstein, MD, John Deanfield, MD, h i j k Alessandro Giardini, MD, PHD, George Porter, MD, PHD, Richard Kim, MD, Amy E. Roberts, MD, k l m m,n Jane W. Newburger, MD, MPH, Elizabeth Goldmuntz, MD, Martina Brueckner, MD, Richard P. Lifton, MD, PHD, o,p,q r,s t d Christine E. Seidman, MD, Wendy K. Chung, MD, PHD, Martin Tristani-Firouzi, MD, H. Joseph Yost, PHD, b u,v Avi Ma’ayan, PHD, Bruce D. Gelb, MD VISUAL ABSTRACT Edwards, J.J. et al. J Am Coll Cardiol Basic Trans Science. 2020;5(4):376–86. ISSN 2452-302X https://doi.org/10.1016/j.jacbts.2020.01.012 JACC: BASIC TO TRANSLATIONALSCIENCEVOL.5,NO.4,2020 Edwards et al. 377 APRIL 2020:376– 86 WAVE2 Complex in LVOTO HIGHLIGHTS ABBREVIATIONS AND ACRONYMS Combining CHD phenotype–driven gene set enrichment and CRISPR knockdown screening in zebrafish is an effective approach to identifying novel CHD genes.
  • Further Clinical and Molecular Delineation of the 15Q24

    Further Clinical and Molecular Delineation of the 15Q24

    Downloaded from jmg.bmj.com on December 30, 2011 - Published by group.bmj.com JMG Online First, published on December 17, 2011 as 10.1136/jmedgenet-2011-100499 Chromosomal rearrangements ORIGINAL ARTICLE Further clinical and molecular delineation of the 15q24 microdeletion syndrome Heather C Mefford,1,2 Jill A Rosenfeld,3 Natasha Shur,4 Anne M Slavotinek,5 Victoria A Cox,5 Raoul C Hennekam,6 Helen V Firth,7 Lionel Willatt,7 Patricia Wheeler,8 Eric M Morrow,9,10 Joseph Cook,1 Rachel Sullivan,11 Albert Oh,12 Marie T McDonald,13 Jonathan Zonana,14 Kory Keller,14 Mark C Hannibal,1,2 Susie Ball,15 Jennifer Kussmann,16 Jerome Gorski,16 Susan Zelewski,17 Valerie Banks,18 Wendy Smith,18 Rosemarie Smith,18 Lindsay Paull,19 Kenneth N Rosenbaum,19 David J Amor,20 Joao Silva,21 Allen Lamb,3 Evan E Eichler22 For numbered affiliations see ABSTRACT INTRODUCTION end of article. Background Chromosome 15q24 microdeletion The introduction of genome-wide approaches to syndrome is a rare genomic disorder characterised by identify deletions and duplications throughout the Correspondence to Dr Heather C Mefford, intellectual disability, growth retardation, unusual facial human genome has facilitated the discovery of Department of Pediatrics, morphology and other anomalies. To date, 20 patients numerous novel causes for intellectual disability Division of Genetic Medicine, have been reported; 18 have had detailed breakpoint (ID), autism, and other developmental disorders.1 2 University of Washington, 1959 analysis. In the clinical work-up of undiagnosed intellectual NE Pacific Street, Box 356320, Aim To further delineate the features of the 15q24 Seattle, Washington DC 98195, disability, array comparative genomic hybridisation USA; microdeletion syndrome, the clinical and molecular (aCGH) has the ability to make a diagnosis in [email protected] characterisation of fifteen patients with deletions in the 10e30% of cases.
  • Supplementary Materials

    Supplementary Materials

    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
  • Cryptococcus Neoformans Can Form Titan-Like Cells in Vitro in Response to Multiple Signals

    Cryptococcus Neoformans Can Form Titan-Like Cells in Vitro in Response to Multiple Signals

    RESEARCH ARTICLE Cryptococcus neoformans can form titan-like cells in vitro in response to multiple signals Nuria Trevijano-Contador1¤, Haroldo Cesar de Oliveira1,2, RocõÂo GarcõÂa-Rodas1, SueÂlen Andreia Rossi1, Irene Llorente1, A ngel Zaballos3, Guilhem Janbon4, JoaquõÂn Ariño5, O scar Zaragoza1* 1 Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain, 2 Universidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, CaÃmpus Araraquara, Departamento de AnaÂlises ClõÂnicas, LaboratoÂrio de Micologia ClõÂnica, Araraquara, São Paulo, Brazil, 3 Genomics Unit, Core Scientific Services, Instituto de Salud Carlos III, a1111111111 Majadahonda, Madrid, Spain, 4 Institut Pasteur, Unite Biologie des ARN des Pathogènes Fongiques, a1111111111 DeÂpartement de Mycologie, Paris, France, 5 Institut de Biotecnologia i Biomedicina and Departament de a1111111111 BioquõÂmica i Biologia Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain a1111111111 a1111111111 ¤ Current address: Albert Einstein College of Medicine, Bronx, New York, United States of America. * [email protected] Abstract OPEN ACCESS Cryptococcus neoformans is an encapsulated pathogenic yeast that can change the size of Citation: Trevijano-Contador N, de Oliveira HC, GarcõÂa-Rodas R, Rossi SA, Llorente I, Zaballos AÂ, the cells during infection. In particular, this process can occur by enlarging the size of the et al. (2018) Cryptococcus neoformans can form capsule without modifying the size of the cell body, or by increasing the diameter of the cell titan-like cells in vitro in response to multiple body, which is normally accompanied by an increase of the capsule too. This last process signals. PLoS Pathog 14(5): e1007007. https://doi. leads to the formation of cells of an abnormal enlarged size denominated titan cells.
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation

    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
  • Comparative Proteomics Analysis of Human Liver Microsomes and S9

    Comparative Proteomics Analysis of Human Liver Microsomes and S9

    DMD Fast Forward. Published on November 7, 2019 as DOI: 10.1124/dmd.119.089235 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 89235 Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions Xinwen Wang, Bing He, Jian Shi, Qian Li, and Hao-Jie Zhu Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan (X.W., B.H., J.S., H.-J.Z.); and School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 210009 (Q.L.) Downloaded from dmd.aspetjournals.org at ASPET Journals on October 2, 2021 1 DMD Fast Forward. Published on November 7, 2019 as DOI: 10.1124/dmd.119.089235 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 89235 Running title: Comparative Proteomics of Human Liver Microsomes and S9 Corresponding author: Hao-Jie Zhu Ph.D. Department of Clinical Pharmacy University of Michigan College of Pharmacy 428 Church Street, Room 4565 Downloaded from Ann Arbor, MI 48109-1065 Tel: 734-763-8449, E-mail: [email protected] dmd.aspetjournals.org Number of words in Abstract: 250 at ASPET Journals on October 2, 2021 Number of words in Introduction: 776 Number of words in Discussion: 2304 2 DMD Fast Forward. Published on November 7, 2019 as DOI: 10.1124/dmd.119.089235 This article has not been copyedited and formatted. The final version may differ from this version. DMD # 89235 Non-standard ABBreviations: DMEs, drug metabolism enzymes; HLM, human liver microsomes; HLS9,
  • NIH Public Access Author Manuscript Expert Opin Drug Metab Toxicol

    NIH Public Access Author Manuscript Expert Opin Drug Metab Toxicol

    NIH Public Access Author Manuscript Expert Opin Drug Metab Toxicol. Author manuscript; available in PMC 2009 March 19. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Expert Opin Drug Metab Toxicol. 2008 June ; 4(6): 697±720. doi:10.1517/17425250802102627. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily Satori A Marchitti, Chad Brocker*, Dimitrios Stagos*, and Vasilis Vasiliou† University of Colorado Health Sciences Center, Molecular Toxicology & Environmental Health Sciences Program, Department of Pharmaceutical Sciences, Denver, Colorado 80262, USA Abstract Background—Aldehydes are highly reactive molecules. While several non-P450 enzyme systems participate in their metabolism, one of the most important is the aldehyde dehydrogenase (ALDH) superfamily, composed of NAD(P)+-dependent enzymes that catalyze aldehyde oxidation. Objective—This article presents a review of what is currently known about each member of the human ALDH superfamily including the pathophysiological significance of these enzymes. Methods—Relevant literature involving all members of the human ALDH family was extensively reviewed, with the primary focus on recent and novel findings. Conclusion—To date, 19 ALDH genes have been identified in the human genome and mutations in these genes and subsequent inborn errors in aldehyde metabolism are the molecular basis of several diseases, including Sjögren-Larsson syndrome, type II hyperprolinemia, γ-hydroxybutyric aciduria and pyridoxine-dependent seizures. ALDH enzymes also play important roles in embryogenesis and development, neurotransmission, oxidative stress and cancer. Finally, ALDH enzymes display multiple catalytic and non-catalytic functions including ester hydrolysis, antioxidant properties, xenobiotic bioactivation and UV light absorption. Keywords aldehyde dehydrogenase; aldehyde metabolism; ALDH 1.
  • Update on the Aldehyde Dehydrogenase Gene (ALDH) Superfamily Brian Jackson,1 Chad Brocker,1 David C

    Update on the Aldehyde Dehydrogenase Gene (ALDH) Superfamily Brian Jackson,1 Chad Brocker,1 David C

    GENOME UPDATE Update on the aldehyde dehydrogenase gene (ALDH) superfamily Brian Jackson,1 Chad Brocker,1 David C. Thompson,2 William Black,1 Konstandinos Vasiliou,1 Daniel W. Nebert3 and Vasilis Vasiliou1* 1Molecular Toxicology and Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA 2Department of Clinical Pharmacy, University of Colorado Anschutz Medical Center, Aurora, CO 80045, USA 3Department of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267, USA *Correspondence to: Tel: þ1 303 724 3520; Fax: þ1 303 724 7266; E-mail: [email protected] Date received (in revised form): 23rd March 2011 Abstract Members of the aldehyde dehydrogenase gene (ALDH) superfamily play an important role in the enzymic detoxifi- cation of endogenous and exogenous aldehydes and in the formation of molecules that are important in cellular processes, like retinoic acid, betaine and gamma-aminobutyric acid. ALDHs exhibit additional, non-enzymic func- tions, including the capacity to bind to some hormones and other small molecules and to diminish the effects of ultraviolet irradiation in the cornea. Mutations in ALDH genes leading to defective aldehyde metabolism are the molecular basis of several diseases, including gamma-hydroxybutyric aciduria, pyridoxine-dependent seizures, Sjo¨gren–Larsson syndrome and type II hyperprolinaemia. Interestingly, several ALDH enzymes appear to be markers for normal and cancer stem cells. The superfamily is evolutionarily ancient and is represented within Archaea, Eubacteria and Eukarya taxa. Recent improvements in DNA and protein sequencing have led to the identification of many new ALDH family members.
  • Molecular Genetic Characterization of Ptr Toxc-Tsc1 Interaction

    Molecular Genetic Characterization of Ptr Toxc-Tsc1 Interaction

    MOLECULAR GENETIC CHARACTERIZATION OF PTR TOXC-TSC1 INTERACTION AND COMPARATIVE GENOMICS OF PYRENOPHORA TRITICI-REPENTIS A Dissertation Submitted to the Graduate Faculty of the North Dakota State University of Agriculture and Applied Science By Gayan Kanishka Kariyawasam In Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Major Department: Plant Pathology November 2018 Fargo, North Dakota North Dakota State University Graduate School Title MOLECULAR GENETIC CHARACTERIZATION OF PTR TOXC-TSC1 INTERACTION AND COMPARATIVE GENOMICS OF PYRENOPHORA TRITICI-REPENTIS By Gayan Kanishka Kariyawasam The Supervisory Committee certifies that this disquisition complies with North Dakota State University’s regulations and meets the accepted standards for the degree of DOCTOR OF PHILOSOPHY SUPERVISORY COMMITTEE: Dr. Zhaohui Liu Chair Dr. Shaobin Zhong Dr. Justin D. Faris Dr. Phillip E. McClean Dr. Timothy L. Friesen Approved: November 7, 2018 Jack Rasmussen Date Department Chair ABSTRACT Tan spot of wheat, caused by Pyrenophora tritici-repentis, is an economically important disease worldwide. The disease system is known to involve three pairs of interactions between fungal-produced necrotrophic effectors (NEs) and the wheat sensitivity genes, namely Ptr ToxA- Tsn1, Ptr ToxB-Tsc2 and Ptr ToxC-Tsc1, all of which result in susceptibility. Many lines of evidence also suggested the involvement of additional fungal virulence and host resistance factors. Due to the non-proteinaceous nature, Ptr ToxC, has not been purified and the fungal gene (s) controlling Ptr ToxC production is unknown. The objective for the first part of research is to map the fungal gene (s) controlling Ptr ToxC production. Therefore, A bi-parental fungal population segregating for Ptr ToxC production was first developed from genetically modified heterothallic strains of AR CrossB10 (Ptr ToxC producer) and 86-124 (Ptr ToxC non-producer), and then was genotyped and phenotyped.